Shares of Eli Lilly (LLY) are moving lower after President Trump said in the Oval Office that the price of GLP-1 weight loss drugs will come down “pretty fast.” Trump noted his administration is negotiating for lower GLP-1 prices. Shares of Eli Lilly are down 4% to $790.12 in post-market trading while Novo Nordisk (NVO) is down 4% to $54.01.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump says cost of GLP-1 drugs to come down ‘pretty fast’, Bloomberg says
- Eli Lilly and Cipla’s Diabetes Study: A Market Game Changer?
- Eli Lilly’s Latest Study on Obesity Treatment: A Promising Update
- Novo Nordisk (NVO) Starts Cutting Jobs in the United States
- Nektar litigation hearing against Lilly delayed, says B. Riley